Empatic Diet Pills (formerly Excalia™) Phase IIb 48 Week Results

On January 7, 2008, Orexigen™ Therapeutics, Inc., announced the 48-week results of the Phase IIb clinical trial of it's weight loss drug, Empatic™. Weight loss through 48 weeks for the highest Empatic dosage arm, in the intent-to-treat, was 14.0% and 15.1%, respectively in the double blind extension and completer groups.

This was Orexigen's first large, multi-center trial of Empatic™, formally known as Excalia™. Empatic™ is a combination of zonisamide and bupropion SR.


Information in this post came from an Orexigen Press release. You can view the entire release at http://ir.orexigen.com/releasedetail.cfm?ReleaseID=284849.

Technorati Tags: Empatic™ Excalia™ Weight Loss Pills Weight Loss DrugsObesityEmpatic™

Empatic Diet Pills (formerly Excalia™) Phase IIb Results

Orexigen™ Therapeutics, Inc., has announced positive results at the 24 week primary endpoint of its Phase IIb trial of Empatic™, formerly known as Excalia™. Empatic™ is one of two promising new drugs Orexigen™ is developing to fight obesity. Using six treatment arms in the trial, Empatic™ showed statistically significant weight loss against placebo in all cases.

Using a combination of zonisamide SR paired with bupropion SR, the discontinuation rate of 14% was significantly lower than previous results which used an immediate release version of zonisamide.

Rates of adverse effects which included headache, nausea, insomnia, anxiety or dry mouth, were consistent with the effects expected with the individual drugs.

Information in this post came from an Orexigen Press release. You can view the entire release at http://ir.orexigen.com/releasedetail.cfm?ReleaseID=256033.

Technorati Tags: Empatic™ Ecalia™ Weight Loss Pills Weight Loss DrugsObesityEmpatic™